GlassScriptPhysician profile
Rajeev Shukla
NPI 1548289630
$15,390.60
in general payments reported to CMS, 2019-2025
45 companies · $2,012 in 2025
The $2,012 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,165 · 2020: $1,420 · 2021: $2,811 · 2022: $2,078 · 2023: $1,976 · 2024: $1,929 · 2025: $2,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,917.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,999.01 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,884.57 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,113.08 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $1,097.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,093.77 | 2019-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $1,033.37 | 2019-2021 | |
| Glaxosmithkline, LLC. | $1,005.95 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $860.86 | 2020-2025 | Qulipta, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $591.78 | 2021-2025 | |
| Corcept Therapeutics | $538.82 | 2024-2025 | Korlym |
| Amgen INC. | $484.62 | 2019-2025 | Krystexxa, Evenity, Prolia |
| Pfizer INC. | $427.21 | 2019-2025 | |
| Allergan, INC. | $400.26 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $387.47 | 2022-2023 | Quviviq |
| Esperion Therapeutics, INC. | $345.35 | 2020-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Shukla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.